TREATMENT OF 22Q11.2 DELETION SYNDROME WITH CANNABIDIOL
The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral and/or psychiatric symptoms of 22q11.2 deletion syndrome are treated in the subject
1 . A method of treating one or more behavioral and/or psychiatric symptoms of 22q11.2 deletion syndrome in a subject, the method comprising:
administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral or psychiatric symptoms of 22q11.2 deletion syndrome are treated in the subject, wherein the effective amount is sufficient to show an improvement, as determined by an Anxiety, Depression, and Mood Scale (ADAMS) assessment or a Pediatric Anxiety Rating Scale (PARS)assessment or a Aberrant Behavior Checklist—Community (ABC-C) assessment, compared to a baseline assessment of the one or more behavioral and/or psychiatric symptoms at the beginning of treatment.
2 . The method of claim 1 , wherein the symptom that is alleviated is anxiety.
3 . The method of claim 1 , wherein the CBD is (-)- CBD.
4 . The method of claim 1 , wherein the effective amount of CBD is between about 50 mg and about 1000 mg total daily.
5 . The method of claim 1 , wherein the effective amount of CBD is about 250 mg total daily.
6 . The method of claim 1 , wherein the effective amount of CBD is about 500 mg total daily.
7 . The method of claim 1 , wherein the effective amount of CBD is about 750 mg total daily.
8 . The method of claim 1 , wherein the CBD is formulated as a gel.
9 . The method of claim 8 , wherein the CBD is formulated as a permeation-enhanced gel.
10 . The method of claim 1 , wherein the CBD is administered in a single daily dose.
11 . The method of claim 1 , wherein the CBD is administered in two daily doses.
12 . The method of claim 1 , wherein the CBD is transdermally.
13 . The method of claim 1 , wherein the CBD is a synthetic CBD.
14 . The method of claim 1 , wherein the CBD is botanically derived.
15 . The method of claim 1 , wherein the CBD is purified.
16 . A method of treating social withdrawal in a subject diagnosed with 22q11.2 deletion syndrome, the method comprising:
administering an effective amount of cannabidiol (CBD) to the subject wherein social withdrawal is treated in the subject, wherein the effective amount is sufficient to show an improvement in social withdrawal, as determined by an Aberrant Behavior Checklist—Community (ABC-C) social withdrawal subscale assessment or an improvement in social avoidance as determined by an Anxiety, Depression, and Mood Scale (ADAMS) assessment, compared to a baseline assessment of social withdrawal, as determined by ABC-C, or a baseline assessment of social avoidance, as determined by ADAMS at the beginning of treatment.
17 . The method of claim 16 , wherein the CBD is (-)- CBD.
18 . The method of claim 16 , wherein the effective amount of CBD is between about 50 mg and about 1000 mg total daily.
19 . The method of claim 16 , wherein the effective amount of CBD is about 250 mg total daily.
20 . The method of claim 16 , wherein the effective amount of CBD is about 500 mg total daily.
21 . The method of claim 16 , wherein the effective amount of CBD is about 750 mg total daily.
22 . The method of claim 16 , wherein the CBD is formulated as a gel.
23 . The method of claim 22 , wherein the CBD is formulated as a permeation-enhanced gel.
24 . The method of claim 16 , wherein the CBD is administered in a single daily dose.
25 . The method of claim 16 , wherein the CBD is administered in two daily doses.
26 . The method of claim 16 , wherein the CBD is transdermally.
27 . The method of claim 16 , wherein the CBD is a synthetic CBD.
28 . The method of claim 16 , wherein the CBD is botanically derived.
29 . The method of claim 16 , wherein the CBD is purified.